Skip to content
value.today
Galectin Therapeutics Inc. logo

Galectin Therapeutics Inc.

GALT
$357 Mmarket cap on Oct 29, 2026+243.4% since Jan 2024
Compare
World rank
#14,029
Revenue
—
For year ending December-2025
Net income
$-31 M
SEC filing
Employees
—

Galectin Therapeutics Inc. in brief

Galectin Therapeutics Inc. is a listed company in the Biotechnology industry, based in Norcross, Georgia, USA. It was founded in 2000. Its market value was $357 M on 29 October 2026, which makes it the 14,029th largest listed company in the world and the 2,748th largest in the USA on this site. Joel Lewis is its chief executive. Its shares trade under the symbol GALT (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Galectin Therapeutics Inc.

We are a clinical stage biopharmaceutical company engaged in drug research and development to create new therapies for fibrotic disease, cancer and selected other diseases. Our drug candidates are based on our method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. We use naturally occurring, readily-available plant products as starting material in manufacturing processes to create proprietary, patented complex carbohydrates with specific molecular weights and other pharmaceutical properties. These complex carbohydrate molecules are appropriately formulated into acceptable pharmaceutical formulations. Using these unique carbohydrate-based candidate compounds that largely bind and inhibit galectin proteins, particularly galectin-3, we are undertaking the focused pursuit of therapies for indications where galectin proteins have a demonstrated role in the pathogenesis of a given disease. We focus on diseases with serious, life-threatening consequences and those where current treatment options are limited specifically in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis and certain cancer indications. Our strategy is to establish and implement clinical development programs that add value to our business in the shortest period of time possible and to seek strategic partners when one of our programs becomes advanced and requires significant additional resources.

From the company's annual report filed with the US SEC: read the report

Galectin Therapeutics Inc. timeline

3 events, 2000–2011
  1. 2000
  2. 🏁
    · approximate
    Founded
  3. 2001
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2011
  6. ✎
    Renamed Galectin Therapeutics Inc
    Formerly Pro Pharmaceuticals Inc.

Events of Galectin Therapeutics Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$100 M$201 M$301 M$402 M2020202120222023202420252026

World rank over time

▲ up 2,725 places since 2020
2020-01-01: #16789#16,78920202021-01-01: #17200#17,20020212022-01-07: #21248#21,24820222022-12-25: #23343#23,34320222023-07-30: #22296#22,29620232024-01-05: #21207#21,20720242026-03-08: #8983#8,98320262026-08-01: #13670#13,67020262026-10-14: #13934#13,93420262026-10-29: #14064#14,0642026

Rank in USA: #3,390 (Jan 2020) · #3,525 (Jan 2021) · #4,224 (Jan 2022) · #4,530 (Dec 2022) · #4,323 (Jul 2023) · #3,668 (Jan 2024) · #1,704 (Mar 2026) · #2,761 (Aug 2026) · #2,721 (Oct 2026) · #2,752 (Oct 2026)

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-14M—FY18Fiscal year ending Dec 2019: revenue —, net income $-13M—FY19Fiscal year ending Dec 2020: revenue —, net income $-23M—FY20Fiscal year ending Dec 2021: revenue —, net income $-31M—FY21Fiscal year ending Dec 2022: revenue —, net income $-39M—FY22Fiscal year ending Dec 2023: revenue —, net income $-41M—FY23Fiscal year ending Dec 2024: revenue —, net income $-47M—FY24Fiscal year ending Dec 2025: revenue —, net income $-31M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-20M$-31M—
Dec 2024——$-42M$-47M—
Dec 2023——$-38M$-41M—
Dec 2022——$-38M$-39M—
Dec 2021——$-30M$-31M—
Dec 2020——$-23M$-23M—
Dec 2019——$-13M$-13M—
Dec 2018——$-14M$-14M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-24M——$-0.48—
Dec 2024$-42M——$-0.76—
Dec 2023$-33M——$-0.74—
Dec 2022$-31M——$-0.65—
Dec 2021$-24M——$-0.52—
Dec 2020$-21M——$-0.41—
Dec 2019$-11M——$-0.39—
Dec 2018$-10M——$-0.38—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024: revenue —, net income $-11M—Sep ’24Three months to Dec 2024 (from the annual report): revenue —, net income $-12M—Dec ’24Three months to Mar 2025: revenue —, net income $-10M—Mar ’25Three months to Jun 2025: revenue —, net income $-8M—Jun ’25Three months to Sep 2025: revenue —, net income $-8M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-6M—Dec ’25Three months to Mar 2026: revenue —, net income $-5M—Mar ’26Three months to Jun 2026: revenue —, net income $-9M—Jun ’26

Latest quarter to Jun 2026: revenue —, net income $-9M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Galectin Therapeutics Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-20 M
Net income
$-31 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$20 M
Total liabilities
$146 M
Total equity
$-128 M

As of December-2025

Top 100 institutional investors in Galectin Therapeutics Inc.#

As of Sep 30, 2026
105 institutions held 16.1 M shares (about 15.9% of the shares outstanding) on Sep 30, 2026. The ten largest hold 11.2%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Galectin Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1BlackRock, Inc.3,378,655+390,302 (+13.06%)3.35%$13 MNov 13, 2026
2Vanguard Capital Management LLC2,092,246-75,819 (-3.50%)2.07%$8 MNov 13, 2026
3Geode Capital Management, LLC1,246,559-61,835 (-4.73%)1.24%$5 MNov 6, 2026
4Osaic Holdings, Inc.1,210,176+6,451 (+0.54%)1.20%$5 MNov 12, 2026
5State Street Corp800,812+233,033 (+41.04%)0.79%$3 MNov 12, 2026
6Wealthspire Advisors, LLC721,7880 (0.00%)0.72%$3 MNov 13, 2026
7Corient Private Wealth LP541,797New0.54%$2 MNov 16, 2026
8Marshall Wace, LLP467,417-363,593 (-43.75%)0.46%$2 MNov 13, 2026
9Commonwealth Equity Services, LLC460,296+53,183 (+13.06%)0.46%$2 MNov 2, 2026
10Northern Trust Corp375,956-10,589 (-2.74%)0.37%$1 MNov 16, 2026
11Vanguard Portfolio Management LLC333,601+5,835 (+1.78%)0.33%$1 MNov 13, 2026
12Vanguard Fiduciary Trust Co333,553-32,923 (-8.98%)0.33%$1 MNov 13, 2026
13LPL Financial LLC285,3800 (0.00%)0.28%$1 MNov 6, 2026
14Sovran Advisors, LLC251,544-6,453 (-2.50%)0.25%$1 MNov 2, 2026
15Geneos Wealth Management Inc.237,691-2,736 (-1.14%)0.24%$1 MNov 9, 2026
16Retirement Guys Formula LLC220,553+9,500 (+4.50%)0.22%$1 MOct 26, 2026
17UBS Group AG213,403-5,916 (-2.70%)0.21%$1 MNov 10, 2026
18Citadel Advisors LLC190,501-8,200 (-4.13%)0.19%$1 MNov 16, 2026
19Charles Schwab Investment Management Inc171,783+55,359 (+47.55%)0.17%$1 MNov 16, 2026
20Blair William & Co/il149,2830 (0.00%)0.15%$1 MNov 10, 2026
21Gsa Capital Partners LLP146,566+17,902 (+13.91%)0.15%$1 MNov 16, 2026
22Goldman Sachs Group Inc138,558+64,004 (+85.85%)0.14%$1 MNov 16, 2026
23Cambridge Investment Research Advisors, Inc.130,384-130,912 (-50.10%)0.13%$1 MNov 2, 2026
24Morgan Stanley127,598+34,123 (+36.50%)0.13%$0 MNov 13, 2026
25National Bank Of Canada /fi/119,300-48,600 (-28.95%)0.12%$0 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Galectin Therapeutics Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Renaissance Technologies LLC110,575+67,232 (+155.12%)0.11%$0 MNov 12, 2026
27Bank of New York Mellon Corp108,367+2,625 (+2.48%)0.11%$0 MNov 5, 2026
28Two Sigma Investments, LP101,748-216,497 (-68.03%)0.10%$0 MNov 16, 2026
29HighTower Advisors, LLC94,760+635 (+0.67%)0.09%$0 MNov 10, 2026
30Creative Planning87,499+76,960 (+730.24%)0.09%$0 MNov 2, 2026
31Nuveen, LLC71,721+8,011 (+12.57%)0.07%$0 MNov 10, 2026
32Hopwood Nicholas Hunter69,270-25 (-0.04%)0.07%$0 MNov 13, 2026
33Truist Financial Corp68,0000 (0.00%)0.07%$0 MOct 30, 2026
34Bank Of America Corp /de/65,087+7,372 (+12.77%)0.06%$0 MNov 16, 2026
35Rhumbline Advisers52,505+4,173 (+8.63%)0.05%$0 MNov 10, 2026
36Horizon Kinetics Asset Management LLC42,452-4,516 (-9.62%)0.04%$0 MNov 12, 2026
37Deutsche Bank AG\42,389-5,014 (-10.58%)0.04%$0 MNov 6, 2026
38Pinnacle Financial Partners, Inc.41,6500 (0.00%)0.04%$0 MNov 13, 2026
39Price T Rowe Associates Inc /MD/39,3130 (0.00%)0.04%$0 MNov 16, 2026
40Sanctuary Advisors, LLC36,983-4,747 (-11.38%)0.04%$0 MNov 13, 2026
41Jpmorgan Chase & Co35,741-1,447 (-3.89%)0.04%$0 MNov 12, 2026
42Pekin Hardy Strauss, Inc.30,0000 (0.00%)0.03%$0 MNov 2, 2026
43Squarepoint Ops LLC28,193New0.03%$0 MNov 9, 2026
44Invesco Ltd.26,283+591 (+2.30%)0.03%$0 MNov 12, 2026
45Solutions 4 Wealth, Ltd25,0270 (0.00%)0.02%$0 MNov 3, 2026
46Gladstone Institutional Advisory LLC23,9000 (0.00%)0.02%$0 MNov 13, 2026
47MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.23,248+1,182 (+5.36%)0.02%$0 MNov 16, 2026
48Cahaba Wealth Management, Inc.21,0000 (0.00%)0.02%$0 MOct 26, 2026
49Mariner, LLC19,360+860 (+4.65%)0.02%$0 MNov 12, 2026
50Stratos Wealth Partners, LTD.19,0880 (0.00%)0.02%$0 MNov 13, 2026
51Barclays PLC18,773+7,196 (+62.16%)0.02%$0 MNov 6, 2026
52Wells Fargo & Company/mn18,337-28,354 (-60.73%)0.02%$0 MNov 16, 2026
53Vanguard Global Advisers, LLC18,283+218 (+1.21%)0.02%$0 MNov 13, 2026
54Archer Investment Corp17,501-17,301 (-49.71%)0.02%$0 MNov 5, 2026
55Wealth Enhancement Advisory Services, LLC17,161+609 (+3.68%)0.02%$0 MOct 13, 2026
56Focus Partners Wealth16,427New0.02%$0 MNov 12, 2026
57MetLife Investment Management, LLC15,818-13,057 (-45.22%)0.02%$0 MNov 16, 2026
58FMR LLC15,439+2,298 (+17.49%)0.02%$0 MNov 10, 2026
59Raymond James Financial Inc14,957+740 (+5.21%)0.01%$0 MNov 12, 2026
60Belpointe Asset Management LLC14,1390 (0.00%)0.01%$0 MNov 9, 2026
61Fortis Capital Advisors, LLC14,1390 (0.00%)0.01%$0 MNov 9, 2026
62Police & Firemen's Retirement System of New Jersey14,1330 (0.00%)0.01%$0 MNov 9, 2026
63New York State Common Retirement Fund13,6000 (0.00%)0.01%$0 MNov 17, 2026
64Sig Brokerage, LP13,5960 (0.00%)0.01%$0 MNov 16, 2026
65Quadrature Capital Ltd13,441New0.01%$0 MNov 13, 2026
66Argyle Capital Partners, LLC13,3750 (0.00%)0.01%$0 MOct 23, 2026
67BNP Paribas Financial Markets12,601+2,385 (+23.35%)0.01%$0 MNov 12, 2026
68Berkshire Money Management, Inc.11,349New0.01%$0 MOct 21, 2026
69Alliancebernstein L.P.11,2000 (0.00%)0.01%$0 MNov 16, 2026
70WINTON GROUP Ltd11,200New0.01%$0 MNov 12, 2026
71Cetera Investment Advisers10,828+828 (+8.28%)0.01%$0 MNov 13, 2026
72Stock Yards Bank & Trust Co10,5000 (0.00%)0.01%$0 MNov 16, 2026
73Integrated Wealth Concepts LLC10,012+12 (+0.12%)0.01%$0 MNov 17, 2026
74Atwood & Palmer Inc10,0000 (0.00%)0.01%$0 MOct 8, 2026
75Simplex Trading, LLC9,720-73,531 (-88.32%)0.01%$0 MNov 4, 2026
76Rockefeller Capital Management L.P.8,864+4,478 (+102.10%)0.01%$0 MNov 13, 2026
77Russell Investments Group, Ltd.8,001+4,027 (+101.33%)0.01%$0 MNov 6, 2026
78Blue Trust, Inc.7,0000 (0.00%)0.01%$0 MOct 15, 2026
79Clearstead Advisors, LLC6,0000 (0.00%)0.01%$0 MNov 6, 2026
80Jones Financial Companies Lllp5,4230 (0.00%)0.01%$0 MNov 13, 2026
81Global Retirement Partners, LLC4,831+4,581 (+1832.40%)0.00%$0 MNov 10, 2026
82Group One Trading LLC4,781-8,972 (-65.24%)0.00%$0 MNov 10, 2026
83Legal & General Group Plc4,6620 (0.00%)0.00%$0 MNov 16, 2026
84Ameritas Investment Partners, Inc.4,3490 (0.00%)0.00%$0 MNov 13, 2026
85CoreCap Advisors, LLC3,8900 (0.00%)0.00%$0 MOct 8, 2026
86Tower Research Capital LLC (TRC)3,530-1,075 (-23.34%)0.00%$0 MNov 16, 2026
87Royal Bank Of Canada2,824+1,192 (+73.04%)0.00%$0 MNov 16, 2026
88Citigroup Inc2,363-20,105 (-89.48%)0.00%$0 MNov 4, 2026
89Activest Wealth Management2,0000 (0.00%)0.00%$0 MOct 15, 2026
90Northwestern Mutual Wealth Management Co1,885-91 (-4.61%)0.00%$0 MNov 13, 2026
91Sterling Capital Management LLC1,373+956 (+229.26%)0.00%$0 MOct 22, 2026
92Hilton Head Capital Partners, LLC8000 (0.00%)0.00%$0 MOct 23, 2026
93Nisa Investment Advisors, LLC7160 (0.00%)0.00%$0 MOct 20, 2026
94California State Teachers Retirement System6600 (0.00%)0.00%$0 MNov 13, 2026
95Fortitude Family Office, LLC3720 (0.00%)0.00%$0 MOct 14, 2026
96Parkside Financial Bank & Trust260New0.00%$0 MOct 27, 2026
97GAMMA Investing LLC166New0.00%$0 MOct 8, 2026
98Jacobi Capital Management LLC125New0.00%$0 MNov 5, 2026
99Allworth Financial LP89New0.00%$0 MNov 17, 2026
100Arax Advisory Partners30New0.00%$0 MNov 12, 2026

All 105 institutional investors, with who bought and sold →

Mutual funds holding Galectin Therapeutics Inc.#

57 funds hold shares worth $23 M (about 5.4% of the company). Since their previous reports 50 added shares and 5 sold, buying $12 M net.
Mutual funds holding Galectin Therapeutics Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.52 M$7 M1.5%<0.01%+13%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors951,470$4 M0.94%<0.01%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.594,705$3 M0.59%<0.01%+5.5%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC520,365$2 M0.52%<0.01%newJul 31, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors309,874$1 M0.31%<0.01%newJun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors160,592$1 M0.16%0.05%+40%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC271,585$1 M0.27%<0.01%−1.8%May 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors112,988$1 M0.11%<0.01%newJun 30, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC89,577$0 M0.09%<0.01%newJun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.116,397$0 M0.12%<0.01%newJul 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC95,489$0 M0.09%<0.01%no changeMay 31, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.48,031$0 M0.05%<0.01%+110%Jun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC47,686$0 M0.05%<0.01%newJun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC78,302$0 M0.08%<0.01%+5.8%May 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC63,710$0 M0.06%<0.01%newJul 31, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation35,800$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC30,807$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.26,902$0 M0.03%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.24,971$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC45,615$0 M0.05%<0.01%no changeMay 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.24,567$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC20,343$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC26,705$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC16,377$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.16,000$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC22,888$0 M0.02%<0.01%newJul 31, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC19,905$0 M0.02%<0.01%+11%Jul 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC12,613$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC10,784$0 M0.01%0.02%+26%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC10,158$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS9,960$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.7,501$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.7,224$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC6,110$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC6,042$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC5,600$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC5,600$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC8,649$0 M<0.01%<0.01%+12%Jul 31, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC4,864$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management4,349$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC3,832$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC3,743$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC3,643$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC5,612$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.5,424$0 M<0.01%<0.01%+4.1%Jul 31, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC4,684$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC2,944$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS4,010$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS3,637$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC2,287$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC1,749$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC2,524$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC1,276$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.1,210$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC1,127$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC700$0 M<0.01%<0.01%−36%Jun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC271$0 M<0.01%<0.01%+8.8%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 57 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Galectin Therapeutics Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$26 K
4 purchases, 2 insiders
Sold, 12 months
$4.0 M
37 sales, 6 insiders
Net, 12 months
-$4.0 M
open market only
Insiders on file
24
since
$35 K-$2.7 M$0Jan 2024: bought $2 K (2 trades), sold $0 (0 trades)Jan 24Apr 2024: bought $14 K (3 trades), sold $77 K (4 trades)Jun 2024: bought $6 K (1 trades), sold $0 (0 trades)JunAug 2024: bought $8 K (3 trades), sold $0 (0 trades)Oct 2024: bought $32 K (4 trades), sold $0 (0 trades)OctDec 2024: bought $35 K (4 trades), sold $97 K (3 trades)Jul 2025: bought $17 K (2 trades), sold $0 (0 trades)JulSep 2025: bought $0 (0 trades), sold $145 K (2 trades)Oct 2025: bought $0 (0 trades), sold $247 K (2 trades)OctNov 2025: bought $0 (0 trades), sold $1.8 M (28 trades)Dec 2025: bought $25 K (3 trades), sold $2.7 M (20 trades)DecJan 2026: bought $0 (0 trades), sold $787 K (9 trades)Feb 2026: bought $810 (1 trades), sold $0 (0 trades)FebMay 2026: bought $0 (0 trades), sold $2 K (1 trades)Jun 2026: bought $0 (0 trades), sold $437 K (6 trades)JunJul 2026: bought $0 (0 trades), sold $83 K (1 trades)
Bought (open market)Sold (open market)Hover a month for the totals
Galectin Therapeutics Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Richard E. UihleinDirector, 10% ownerOption exerciseindirect+31.83 M$3.000$95.5 M42.16 MForm 4
filed Richard E. UihleinDirector, 10% ownerOption exerciseindirect+2.55 M$4.050$10.3 M44.71 MForm 4
filed Khurram JamilChief Medical OfficerOption exercise10b5-1 plan+16,250$3.040$49 K16,250Form 4
filed Khurram JamilChief Medical OfficerSell10b5-1 plan-16,250$5.130$83 K0Form 4
filed Harold H. ShlevinDirectorOption exercise10b5-1 plan+22,268$1.230$27 K28,768Form 4
filed Harold H. ShlevinDirectorSell10b5-1 plan-22,268$5.040$112 K6,500Form 4
filed Khurram JamilChief Medical OfficerOption exercise10b5-1 plan+47,467$2.500$119 K47,467Form 4
filed Khurram JamilChief Medical OfficerSell10b5-1 plan-47,467$5.040$239 K0Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Galectin Therapeutics Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
9.0 M
13.8% of shares · 46.26 days to cover
Shares sold short, last 24 reportsAll stocks →

Trading halts

  • 2025-06-20 13:43 UTC, code LUDP, resumed 13:48 UTC
  • 2025-06-20 13:31 UTC, code LUDP, resumed 13:36 UTC

Fails to deliver

  • : 5,567 shares at $3.54
  • : 6,166 shares at $3.38
  • : 10,478 shares at $3.19
  • : 289 shares at $3.37
  • : 21,077 shares at $3.43

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Galectin Therapeutics Inc. scorecard#

Passes 1 of the 11 checks that could be worked out. Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-4.8%Free cash flow is -4.8% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-0.48 vs -0.76Diluted EPS -0.48 in fiscal 2025 against -0.76 the year before (report's currency).
    • ✗Net income higher than five years earlier-$31 M-$31 M in fiscal 2025 against -$23 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$31 MNet income -$31 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities2.4×Current ratio 2.42 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year2.6%Diluted shares up 2.6% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Galectin Therapeutics Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Galectin Therapeutics Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Research and development1437323224187.56.51215
General and administrative5.85.95.96.66.45.56.07.14.56.2
Operating expenses20423838302313141621
Operating income−20−42−38−38−30−23−13−14−16−21
Interest and finance income0.10.30.20.10.00.10.20.00.00.0
Interest expense and finance costs7.35.52.81.00.50.10.10.30.0—
Other non-operating income (expense)−11−4.6−3.0−0.4−0.3−0.00.1−0.30.00.0
Income tax00————————
Net income attributable to shareholders−31−47−41−39−31−23−13−14−16−21
Earnings per share, basic-0.48-0.76-0.74-0.65-0.52-0.41-0.39-0.38-0.49-0.76
Earnings per share, diluted-0.48-0.76-0.74-0.65-0.52-0.41-0.39-0.38-0.49-0.76
Shares, weighted average (basic)646260595957————
Shares, weighted average (diluted)64626059595752393629
Balance sheet
Cash and cash equivalents181526194027478.33.115
Other current assets1.72.12.12.02.22.30.70.60.80.4
Current assets191728214229488.83.816r
Property, plant and equipment0000000000
Right-of-use (leased) assets0.00.00.0r0.10.0—————
Other intangible assets———————000.0
Total assets201728214230489.04.216
Accounts payable3.25.76.43.91.81.31.70.30.60.9
Current liabilities8.03516139.05.42.82.13.03.8
Lease liabilities (non-current)——0.00.1——————
Total liabilities1461218853395.42.92.13.03.8
Retained earnings−433−402−354−310−271−240−216−196−181−164
Shareholders' equity−128−105−62−340.922445.2−0.510
Total liabilities and equity201728214230489.04.216
Shares outstanding65636259595757413633
Cash-flow statement
Depreciation and amortization—00000000.00.0
Share-based compensation1.72.42.32.92.11.81.74.41.12.5
Cash from operating activities−24−42−33−31−24−21−11−10−16−16
Cash from investing activities000000—000
Shares issued3.20—06.80.350153.65.9
Cash from financing activities26314010370.350153.65.9
Change in cash———————5.2−12−10
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Galectin Therapeutics Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.2 M
Joel Lewis
Other top executives, average
$929 K
the CEO earned 1.3× this
$100 invested is now
$322
Galectin Therapeutics Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Joel Lewis$1.2 M$1.7 M$929 K$322
2024Joel Lewis$1.2 M$1.1 M$831 K$78
2023Joel Lewis$964 K$1.1 M$666 K$147

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Galectin Therapeutics Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Directors and officers 4 · Material agreement 2 · Unregistered share sale 1 · Shareholder vote 2 · Results announced 8

Galectin Therapeutics Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Unregistered share sale8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K
Material agreement8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officersMaterial agreement8-K
Results announced8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Aug 14, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Galectin Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Dec 2016$3 MPrivate placement after listing$2 to $10 million5equity, optionsSEC
Sep 2016$2 MPrivate placement after listingUnder $2 million1equity, optionsSEC
Dec 2010$2 MNo. 1$2 to $10 million22equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

How Galectin Therapeutics Inc. compares in Biotechnology

  • Market cap$357 M · higher than 54% of 726
  • FCF yield-4.8% · higher than 73% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Galectin Therapeutics Inc.🇺🇸$357 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Galectin Therapeutics Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Galectin Therapeutics Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Galectin Therapeutics Inc.? Suggest a correction